A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 55,122 shares of DAWN stock, worth $705,010. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,122
Previous 51,891 6.23%
Holding current value
$705,010
Previous $715,000 7.27%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.72 - $16.03 $41,098 - $51,792
3,231 Added 6.23%
55,122 $767,000
Q2 2024

Aug 14, 2024

BUY
$12.03 - $17.69 $99,861 - $146,844
8,301 Added 19.04%
51,891 $715,000
Q1 2024

May 15, 2024

BUY
$13.56 - $17.46 $138,623 - $178,493
10,223 Added 30.64%
43,590 $720,000
Q4 2023

Feb 14, 2024

BUY
$9.68 - $15.37 $322,992 - $512,850
33,367 New
33,367 $487,000
Q2 2023

Aug 14, 2023

BUY
$11.74 - $14.47 $199,990 - $246,496
17,035 Added 153.08%
28,163 $336,000
Q1 2023

May 15, 2023

BUY
$12.75 - $23.41 $141,882 - $260,506
11,128 New
11,128 $149,000
Q3 2022

Nov 14, 2022

BUY
$16.44 - $26.57 $600,783 - $970,974
36,544 New
36,544 $732,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $940M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.